WorldEnquirer.com
Legally Crooked book www.legallycrooked.com
Welcome the World Enquirer Message Board
Sign up  |   |   |  Calendar  |  Latest Topics
 
 
 


Reply
  Author   Comment  
Tailwinds_Research

Registered:
Posts: 8
 #1 
All, ITUS was recently added to the Tailwinds Select Portfolio. All Tailwinds research on ITUS is available at http://www.tailwindsresearch.com/itus/

The first piece on ITUS details their diagnostic efforts. This weekend, Part II will come out discussing their potential CAR-T license, which, should they manage to secure it, will be an exciting opportunity for the company. 

__________________
Daniel Carlson
glhayes

Registered:
Posts: 2,333
 #2 
Happy,

Thank you for excellent commentary based upon reading road kill autopsy results with hope. 
Modinegee

Registered:
Posts: 111
 #3 
https://ir.ituscorp.com/press-releases/detail/864
long4copy

Registered:
Posts: 238
 #4 
do we need to fill the gap open?
glhayes

Registered:
Posts: 2,333
 #5 
Someone's recent post mentioned "illegal naked shorting-bulls"  IMO it has an implied contradiction and was irresponsible. 
Modinegee

Registered:
Posts: 111
 #6 
https://ir.ituscorp.com/press-releases/detail/865
horace_schit

Registered:
Posts: 2,281
 #7 
before you get all excited about your kitchenware, hapy, it is moving up today because of news.  plain and simple.
Modinegee

Registered:
Posts: 111
 #8 
Thank You....Liz/Red



https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536094/
Modinegee

Registered:
Posts: 111
 #9 

Again...Thanks Liz/Red


Conclusions

In a short time, CAR T cells have advanced from the bench to the bedside. The early-phase clinical trials revealed dramatic efficacy with durable remissions in patients with acute leukemias refractory to standard salvage chemotherapies. In the next couple of years, the first gene-modified cell therapy will likely be approved, with an indication for B-cell malignancies. As CAR T-cell evaluation expands to multicenter phase 2 trials, the clinical expertise with this therapy will broaden. Other academic medical centers will mirror our institutions (Moffitt and Memorial Sloan Kettering), which have developed dedicated medical services to administer this therapy and manage the patients. With the ongoing development of multiple treatment sites, we expect further breakthroughs in understanding the nature of the toxicities and developing targeted supportive therapies that minimize the complications while preserving the therapeutic benefits. Furthermore, exciting preclinical work describing the next-generation of CAR T-cell therapeutics will hopefully allow this innovative, living drug to target not only B-cell malignancies, but other hematologic malignancies and solid tumors as well.

Previous Topic | Next Topic
Print
Reply

Quick Navigation:

Easily create a Forum Website with Website Toolbox.